Clinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer

被引:0
|
作者
Christopoulos, P. [1 ]
Kohlhaeufl, J. [1 ]
Bozorgmehr, F. [1 ]
Kuon, J. [1 ]
Schneider, M. [1 ]
Neumann, O. [1 ]
Liersch, S. [1 ]
Heussel, C. [1 ]
Winter, H. [1 ]
Herth, F. [1 ]
Rieken, S. [2 ]
Muley, T. [1 ]
Meister, M. [1 ]
Bischoff, H. [1 ]
Lasitschka, F. [1 ]
Stenzinger, A. [3 ]
Thomas, M. [1 ]
机构
[1] Thoraxklin Heidelberg, Oncol, Heidelberg, Germany
[2] Univ Hosp Heidelberg, Radiat Oncol, Heidelberg, Germany
[3] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
10P
引用
收藏
页数:2
相关论文
共 50 条
  • [41] The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe, Hiromi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kudo, Kenichiro
    Minami, Daisuke
    Murakami, Etsuko
    Ochi, Nobuaki
    Ninomiya, Takashi
    Harada, Daijiro
    Yasugi, Masayuki
    Ichihara, Eiki
    Ohashi, Kadoaki
    Fujiwara, Keiichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Modifiable biomarkers of response to immune checkpoint inhibitor treatment in non-small cell lung cancer
    Spakowicz, D.
    Williams, N.
    Bibi, A.
    Hoyd, R.
    Wheeler, C. E.
    Suman, S.
    Amann, J.
    Okimoto, T.
    Grogan, M.
    Vibhakar, P.
    Owen, D.
    Carbone, D. P.
    Presley, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S345 - S346
  • [43] Acute hyponatremia from immune checkpoint inhibitor therapy for non-small cell lung cancer
    Desikan, Sai Prasad
    Varghese, Ron
    Kamoga, Roy
    Desikan, Raman
    POSTGRADUATE MEDICAL JOURNAL, 2020, 96 (1139) : 570 - 571
  • [44] Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
    Hao, Yuxuan
    Zhang, Xiaoye
    Yu, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
    Xiaoling Shang
    Wengang Zhang
    Wenfei Han
    Handai Xia
    Ni Liu
    Xiuwen Wang
    Yanguo Liu
    BMC Pulmonary Medicine, 23
  • [46] Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
    Shang, Xiaoling
    Zhang, Wengang
    Han, Wenfei
    Xia, Handai
    Liu, Ni
    Wang, Xiuwen
    Liu, Yanguo
    BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [47] Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer
    Nakahama, Kenji
    Izumi, Motohiro
    Yoshimoto, Naoki
    Fukui, Mitsuru
    Sugimoto, Akira
    Nagamine, Hiroaki
    Ogawa, Koichi
    Sawa, Kenji
    Tani, Yoko
    Kaneda, Hiroyasu
    Mitsuoka, Shigeki
    Watanabe, Tetsuya
    Asai, Kazuhisa
    Kawaguchi, Tomoya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (05) : 381 - 390
  • [48] Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
    Nishiyama, Osamu
    Shimizu, Shigeki
    Haratani, Koji
    Isomoto, Kosuke
    Tanizaki, Junko
    Hayashi, Hidetoshi
    Yamazaki, Ryo
    Oomori, Takashi
    Nishikawa, Yusaku
    Sano, Akiko
    Nakagawa, Kazuhiko
    Tohda, Yuji
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [49] Clinical predictive markers of response to immune checkpoint inhibitor therapy in advanced non-small cell lung cancer.
    Rhone, Raena
    Dumais, Katerine
    Powery, Herman W.
    Gentile, Frank
    Raez, Luis E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer
    Kenji Nakahama
    Motohiro Izumi
    Naoki Yoshimoto
    Mitsuru Fukui
    Akira Sugimoto
    Hiroaki Nagamine
    Koichi Ogawa
    Kenji Sawa
    Yoko Tani
    Hiroyasu Kaneda
    Shigeki Mitsuoka
    Tetsuya Watanabe
    Kazuhisa Asai
    Tomoya Kawaguchi
    Cancer Chemotherapy and Pharmacology, 2023, 92 : 381 - 390